ArticleBMC nephrology2025
Thrombotic microangiopathy associated with mantle cell lymphoma: a case report.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThrombotic microangiopathy (TMA) is a syndrome characterized by vascular endothelial cell damage, with anemia, thrombocytopenia, and thrombus-related organ damage. Secondary TMA is caused by various factors, including hematological malignancy. Case reports on TMA with mantle cell lymphoma (MCL) are extremely rare. Herein, we report a case of secondary TMA wherein MCL was diagnosed based on the same kidney biopsy specimen and treated with chemotherapy, resulting in improvement in TMA. CASE PRESENTATION: A 60-year-old man was admitted to our hospital for acute kidney injury with TMA and focal interstitial lymphocytic infiltration, which was detected by kidney biopsy performed at a previous hospital. Plasma exchange, hemodialysis, and steroid therapy were initiated; however, the TMA did not improve. Immunostaining of the kidney biopsy specimen revealed MCL; chemotherapy was initiated, which improved the thrombocytopenia and hemolysis.
conclusionsTo our best knowledge, this is a very rare case of secondary TMA owing to MCL wherein chemotherapy was effective, suggesting a causal relationship. Kidney biopsy was key to identifying the underlying malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.